We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC System Could Transform Infectious Disease Management

By LabMedica International staff writers
Posted on 27 May 2022
Print article
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)

A new platform supports rapid, efficient and accurate diagnosis of multiple infectious diseases, aiding clinical decision-making, and enabling improved, timely access to healthcare for all.

DRW’s (Diagnostics for the Real World, Cambridge, UK) SAMBA II is a robust, simple-to-use system offers a complete end-to-end process, delivering fast results and reducing the typical 1-2 day wait from centralized laboratory tests. The SAMBA II system delivers a true point-of-care system, from sample extraction, through to isothermal nucleic acid amplification, patented lateral flow detection and automated interpretation of results.

SAMBA II is a real game changer in infectious disease management. It is fully automated, performing sample preparation, extraction, amplification and detection: a true sample in – result out system. With SAMBA II, high-tech diagnostic and treatment monitoring assays become easy to perform and require minimal training. While-you-wait results enable test and treat facilities, enhancing the way diseases are managed. Safe and easy to use, the uniquely shaped ready-to use cartridges are easy to load and include all consumables. The visual results are automatically analyzed by the integrated camera to ensure consistent and accurate interpretation, with results presented and stored on the connected tablet. SAMBA II delivers innovative assays in an easy-to-use and accessible platform for the diagnosis and treatment monitoring of infectious disease at the point of care, including HIV, SARS-CoV-2, hepatitis B and C, and influenza A and B.

The SAMBA II system is comprised of the assay module, where the test is performed, and the tablet module, which controls the assay module and displays the test results. Each tablet module can control up to four assay modules, allowing flexibility and scalability at sites using SAMBA II. SAMBA II is a connected platform. The tablet module controls the assay module and receives all results via Bluetooth. The tablet module can send results to the Bluetooth printer, or via SMS, mobile Internet or Wi-Fi to a backup tablet or a tablet in a remote clinic who send their samples to be tested with SAMBA II. The tablet module can also send test results in a standard format to a laboratory information system (LIS), to a Ministry of Health service or to the SAMBA dashboard. Test results can also be downloaded directly from the tablet via USB. With SAMBA II, test results can be sent to those that need them.

Related Links:
DRW 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more